New combo therapy aims to stop liver cancer return in High-Risk patients
NCT ID NCT07186621
First seen Nov 01, 2025
Summary
This Phase 3 trial tests whether combining radiotherapy with the immunotherapy drug sintilimab can better prevent liver cancer from coming back after surgery, compared to the standard TACE procedure. The study enrolls 286 patients with high-risk features like narrow surgical margins. Participants will receive either the combination therapy or TACE, and researchers will track cancer recurrence and survival over two years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sintilimab (an immunotherapy drug) and radiotherapy
What this could lead to
If successful, this could offer a more effective way to prevent liver cancer from returning after surgery, potentially improving long-term survival.
What could go wrong
This is a Phase 3 trial, but it's still experimental. The combination may cause side effects like immune-related inflammation, and it's unclear if it will outperform the standard TACE approach.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.